Abstract library

13 results for "somatostatinoma".
#224 Primary Renal Somatostatinoma with Hepatic Metastases
Introduction: Somatostatinomas are rare gastroenteropancreatic neuroendocrine tumors (GEP-NET) with a primary lesion that is invariably localized to the pancreas (40%) or duodenum or jejunum (50%).
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: Dr Richard W Carroll
#340 Aggressive Somatostatinoma, with Associated Pheocromocytoma in a Neurofibromatosis Patient
Introduction: Neurofibromatosis is associated with a neuroendocrine phenotype as pheocromocytoma, primary hyperparathyroidism and gastropancreatic neuroendocrine tumors.
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: Catalina Poiana
Authors: Poiana C, Carsote M, Radoi V, Ene C, ...
#279 Coexistence of a Somatostatin-Producing Carcinoma of Duodenum and a Jejuna Gastrointestinal Stromal Tumor (GIST) in a Patient with Von Recklinghausen’s Disease
Introduction: Duodenal neuroendocrine tumors comprise 2-3% of all neuroendocrine tumors of the gastrointestinal tract. Coexistence of NF-1, NET and GIST is rare and only five cases have been described in the literature.
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: Dr Vasiliki Daraki
#1785 Eterogeneity of Duodenal Neuroendocrine Tumors: A Multi-Centre Experience in Italy
Introduction: Duodenal neuroendocrine neoplasms (dNENs) are heterogeneous tumors, which could have a highly variable prognosis.
Conference: 14th Annual ENETS conference (2017)
Category: Epidemiology/Natural history/Prognosis - Prognosis
Presenting Author: dr Sara Massironi
#2138 Eterogeneity of Duodenal Neuroendocrine Tumors: A Multi-Centre Experience In Italy
Introduction: The optimal management of duodenal neuroendocrine neoplasms (dNENs) is unclear and endoscopic resection is increasingly performed instead of surgery.
Conference: 15th Annual ENETS conference (2018)
Category: Epidemiology/Natural history/Prognosis- Registries, nationwide and regional surveys
Presenting Author: MD Roberta Elisa Rossi
#106 Gastroenteropancreatic neuroendocrine tumors: single institution clinicopathological study
Introduction: Neuroendocrine cells are widely distributed throughout the body, and neoplasms from these dispersed cells can arise at many sites. They are distinguished into two broad categories: 1) Tumors identified as small cell lung carcinomas with biology and natural history of a high-grade malignancy and characteristics of small cell undifferentiated or anaplastic appearance by light microscopy. The WHO categorizes these tumors as poorly-differentiated neuroendocrine carcinomas; 2) Well-defined neuroendocrine tumors (NETs) with variable, but most lyindolent biologic behavior and characteristic well-differentiated histologic features. The majority arise in the gastrointestinal tract and collectively they are referred as gastroenteropancreatic neuroendocrine tumors (GEP/NETs). They include carcinoid tumors, pancreatic islet cell tumors (gastrinoma, insulinoma, glucagonoma, VIPoma, somatostatinoma), paragangliomas, pheochromocytomas, and medullary thyroid carcinomas. The WHO classifies the GEP/NETs as well-differentiated NETs (carcinoid tumors) if they are noninvasive and have benign behavior or uncertain malignant potential. In contrast, GEP/NETs with characteristics of low-grade malignancy with invasion of the muscularis propria or beyond, or metastases, are characterized as well-differentiated neuroendocrine carcinomas (malignant carcinoids). Pancreatic islet cell tumors, whether functioning or not, are classified as well-differentiated NETs or well-differentiated neuroendocrine carcinomas, due to the (depending on) histologic characteristics. The WHO classification for gastroenteropancreatic NETs based on stage (ie size and presence of metastases) and grade (mitotic rate, perineural and lymphovascular invasion, Ki-67 proliferative index) categorizes them as well-differentiated NETs, e.g., carcinoid tumors, or as well-differentiated neuroendocrine carcinomas.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Dr Michael M. Vaslamatzis
#203 Liver and Liver-Pancreastransplantation in the Two-stage Treatment of Liver Metastasized Neuroendocrine Tumors of the Pancreas: About Three Cases
Introduction: Although liver transplantation is a valid option in the treatment of metastasized neuroendocrine tumors, it is not promoted because of a donor organ shortage and disappointing results in older series.
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: Dr. Geert Roeyen
#221 Diagnostic Algorithm of Pancreatic Neuroendocrine Tumors
Introduction: Diagnostics of pNETs is associated with certain problems due to a variety of clinical features, including a rather small size of primaries and, quite often, multiple lesions.
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: Ivan A Vasiliev
#324 Well-differentiated Pancreatic Neuroendocrine Tumor of Uncertain Behavior: A Case Report
Introduction: A small number of Pancreatic Endocrine Tumors (PET) are well-differentiated tumors(WDET) showing benign or uncertain behavior. Prognosis mainly depends on the presence/absence of liver/bone metastasis.
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: Dr. Joana Couto
#419 Morphological Characteristics of Pancreatic Tumors in Children and Young Patients
Introduction: Pancreatic tumors (PT) usually occur after age 60 and almost never in children and young patients (pts). Little is known concerning frequency, morphological and immunohistochemical (IHC) characteristics of PTs in children and young pts.
Conference: 9th Annual ENETS Conference (2012)
Category: Basic
Presenting Author: I Voronkova